Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Donghan Luo"'
Autor:
Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy
Publikováno v:
HIV Research & Clinical Practice, Vol 22, Iss 2, Pp 55-61 (2021)
Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/saf
Externí odkaz:
https://doaj.org/article/04000d73446f4fdd8103c85c2ad64480
Autor:
Keith Dunn, Bryan Baugh, Nika Bejou, Donghan Luo, Jennifer Campbell, Sareh Seyedkazemi, David Anderson
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 21 (2022)
Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through
Externí odkaz:
https://doaj.org/article/795180296fca4a059a4dd38f80a83900
Autor:
Erkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, Kimberley Brown, Sandra De Meyer, Eric Y. Wong
Publikováno v:
HIV Research & Clinical Practice, Vol 21, Iss 2-3, Pp 83-89 (2020)
Background The efficacy and high barrier to resistance of darunavir have been demonstrated across diverse populations with HIV-1 infection. Objective To evaluate post-baseline resistance among patients in studies of once-daily (QD) darunavir-based re
Externí odkaz:
https://doaj.org/article/c59070e583c6421891f8058776002563
Autor:
Gregory D. Huhn, Joseph J. Eron, Pierre-Marie Girard, Chloe Orkin, Jean-Michel Molina, Edwin DeJesus, Romana Petrovic, Donghan Luo, Erika Van Landuyt, Erkki Lathouwers, Richard E. Nettles, Kimberley Brown, Eric Y. Wong
Publikováno v:
AIDS Research and Therapy, Vol 16, Iss 1, Pp 1-11 (2019)
Abstract Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. The efficacy/safety of switching to D/C/F/TAF versus continuing booste
Externí odkaz:
https://doaj.org/article/80dc76c7a758457497a6a560752f9d44
Autor:
Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong
Publikováno v:
HIV Research & Clinical Practice, Vol 20, Iss 1, Pp 24-33 (2019)
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-week efficacy and safety of D/C/F/TAF versus darunavir/c
Externí odkaz:
https://doaj.org/article/2398a84fc10a4d59a8c3ed8590f56b34
Autor:
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Publikováno v:
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Abstract Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhoti
Externí odkaz:
https://doaj.org/article/61e6a0119abd4699b62cba409899ce21
Publikováno v:
HIV Medicine. 24:279-289
Autor:
Donghan Luo, Richard Bruce Simonson, Moti Ramgopal, Richard E. Nettles, Carmela Benson, Keith Dunn, Joseph Gathe, Robert K. Bolan, Gregory D Huhn, Gordon Crofoot
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Most guidelines recommend rapid treatment initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir/cobicistat/e
Autor:
Kimberley Brown, Edwin DeJesus, Richard E. Nettles, Erkki Lathouwers, Romana Petrovic, Gregory D Huhn, Donghan Luo, Jean-Michel Molina, Eric Y Wong, Joseph J. Eron, Erika Van Landuyt, Chloe Orkin, Pierre-Marie Girard
Publikováno v:
AIDS Research and Therapy, Vol 16, Iss 1, Pp 1-11 (2019)
AIDS Research and Therapy
AIDS Research and Therapy, BioMed Central, 2019, 16 (1), pp.23. ⟨10.1186/s12981-019-0235-1⟩
AIDS Research and Therapy
AIDS Research and Therapy, BioMed Central, 2019, 16 (1), pp.23. ⟨10.1186/s12981-019-0235-1⟩
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. The efficacy/safety of switching to D/C/F/TAF versus continuing boosted proteas
Autor:
Cheryl McDonald, Cristina Mussini, Donghan Luo, Eric Y Wong, Christoph D. Spinner, Kimberley Brown, John Jezorwski, Erika Van Landuyt, Bruce Rashbaum
Publikováno v:
HIV Research & Clinical Practice. 20:24-33
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-wee...